Fig. 4.

Survival analysis and clinical outcomes of HER2-0 and HER2-low MBC patients. a Assessment of the efficacy of TX regimen chemotherapy with HER2-0 and HER2-low MBC patients. b The bTMB and mTBI values of baseline (BL) and after the initial two treatment cycles (T1) of the groups. c OS analysis based on the mTBI after the initial two treatment cycles of HER2-low MBC. d OS analysis of HER2-low MBC patients with or without ctDNA cleared after the initial two treatment cycles. e The impact of HER2-0 and HER2-low MBC, with or without MRG mutations, on the alteration of DCR. f, g PFS/OS analysis of HER2-0 and HER2-low MBC with MRG mutations. h PFS analysis of HER2-0 and HER2-low MBC patients with MRG mutations who were treated with adjuvant endocrine therapy. i PFS analysis of HER2-0 and HER2-low MBC patients with MRG mutations who were treated with CDK4/6 inhibitor. *P < 0.05